Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nicole Szuminski
Institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University
Observed institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University
ORCID:
0009-0003-2364-1628
Observed ORCID:
0009-0003-2364-1628
OpenAlex ID:
A5140593612
A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)
2022
·
Sumithira Vasu
, Lapo Alinari
, et al.
·
Blood
·
8
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2021
·
Sumithira Vasu
, Nidhi Sharma
, et al.
·
Blood
·
7
Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
2024
·
Sumithira Vasu
, Evandro Bezerra
, et al.
·
Blood
·
4
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2020
·
Sumithira Vasu
, Bhavana Bhatnagar
, et al.
·
Blood
·
3
SAR445419 Off-the-Shelf Natural Killer Cells Are Safe and Show Efficacy Signal in Relapsed/Refractory Acute Myeloid Leukemia.
2024
·
Sumithira Vasu
, Nicole Szuminski
, et al.
·
Transplantation and Cellular Therapy
·
2
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
·
Blood Cancer Discovery
·
1
PDF
Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Clinical Protocol 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Data from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
First report of successful, lifesaving and timely graft rescue using an off-the-shelf cryopreserved, cadaveric marrow in myeloablative transplant with an unexpected unavailability of a living matched unrelated donor.
2025
·
Sumithira Vasu
, Nicole Szuminski
, et al.
·
Blood
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Third-Party Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2022
·
Sumithira Vasu
, Nidhi Sharma
, et al.
·
Transplantation and Cellular Therapy
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2021
·
Sumithira Vasu
, Bhavana Bhatnagar
, et al.
·
Transplantation and Cellular Therapy
Show more works
View as search
Works count:
20
Citation count:
25
H-index:
3
I10-index:
Year
Topic
Type